Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 4/20 | 0.41 |
| ▸ | CES1 | P23141 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | PAM | P19021 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10595444 | 0.98 | HAO1 (0.52) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL29022869 | 0.98 | HAO1 (0.52) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL10799382 | 0.98 | HAO1 (0.52) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL1562138 | 0.98 | HAO1 (0.52) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL1562098 | 0.98 | HAO1 (0.52) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL562503 | 0.96 | HAO1 (0.46) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL14604888 | 0.94 | HAO1 (0.41) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL10799584 | 0.89 | FAAH (0.55) | MAPTKMT2ALMNAFAAHPOLB | |
| SCHEMBL10799580 | 0.89 | FAAH (0.55) | MAPTKMT2ALMNAFAAHPOLB | |
| SCHEMBL6415291 | 0.86 | ALDH1A1 (0.41) | CES2CES1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751095-B1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2021-10-27 | — | — | EP | disclosed |
| US-9193710-B2 | Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150025064-A1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-22 | — | — | US | disclosed |
| EP-2751095-A2 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | Sanford-Burnham Medical Research Institute (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033246-A2 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | BRAINCELLS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-8163713-B2 | Trehalose compound and pharmaceutical comprising the compound | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2137167-B1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2000473-B1 | TREHALOSE COMPOUND AND PHARMACEUTICAL COMPRISING THE COMPOUND | OTSUKA CHEMICAL CO LTD (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20100249057-A1 | TREHALOSE COMPOUND AND PHARMACEUTICAL COMPRISING THE COMPOUND | OTSUKA CHEMICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2137167-A1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-12-30 | — | — | EP | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
| CN-1379764-A | Benzodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 2002-11-13 | — | — | CN | disclosed |
| CN-1379765-A | Benzodiazepine derivatives usable as parental metabolic glutamate receptor antagonist | HOFFMANN LA ROCHE (CH) | 2002-11-13 | — | — | CN | disclosed |
| WO-2002083652-A1 | DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083665-A1 | DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| EP-1224174-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| US-6407094-B1 | 4-5-DIDEHYDRO-1,5-BENZODIAZEPIN-2-ONE DERIVATIVES; PSYCHOLOGICAL, NERVOUS SYSTEM, AND BRAIN DISORDERS; COGNITION ACTIVATORS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029011-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249057-A1 | TREHALOSE COMPOUND AND PHARMACEUTICAL COMPRISING THE COMPOUND | ADORA3, TREH, ADORA1 | HAO1 1955/4885MAPT 2956/4885KMT2A 4766/4885 |
| US-20150025064-A1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | GRM1, GRM3, GRM2 | HAO1 4200/4885MAPT 1748/4885KMT2A 1326/4885 |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | HAO1 955/4885MAPT 1155/4885KMT2A 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.